DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer

BACKGROUND: Sotorasib is the first KRAS(G12C) inhibitor approved by the US Food and Drug Administration for treating KRAS(G12C)-mutant non-small-cell lung cancer (NSCLC). Clinical trials on the therapeutic use of sotorasib for cancer have reported promising results. However, KRAS(G12C)-mutant cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiou, Li-Wen, Chan, Chien-Hui, Jhuang, Yu-Ling, Yang, Ching-Yao, Jeng, Yung-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308767/
https://www.ncbi.nlm.nih.gov/pubmed/37386628
http://dx.doi.org/10.1186/s12929-023-00940-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308767/
https://www.ncbi.nlm.nih.gov/pubmed/37386628
http://dx.doi.org/10.1186/s12929-023-00940-4

Ejemplares similares